Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

oleclumab (MEDI9447)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

CD73 inhibitor

Related drugs:

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	durvalumab + MEDI9447 Sensitive: C2 – Inclusion Criteria durvalumab + MEDI9447 Sensitive : C2	durvalumab + MEDI9447 Sensitive: C2 – Inclusion Criteria durvalumab + MEDI9447 Sensitive : C2
EGFR exon 18 deletion	Non Small Cell Lung Cancer	EGFR exon 18 deletion	Non Small Cell Lung Cancer	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	MEDI9447 Sensitive: C3 – Early Trials MEDI9447 Sensitive : C3	MEDI9447 Sensitive: C3 – Early Trials MEDI9447 Sensitive : C3
CD73 elevation	Triple Negative Breast Cancer	CD73 elevation	Triple Negative Breast Cancer	durvalumab + MEDI9447 Resistant: C3 – Early Trials durvalumab + MEDI9447 Resistant : C3	durvalumab + MEDI9447 Resistant: C3 – Early Trials durvalumab + MEDI9447 Resistant : C3